Nionyx Bio

Nionyx Bio, based in the US, specializes in innovative gene therapy solutions aimed at enhancing precision and safety in the delivery of genetic materials, focusing on kidney-related conditions. Nionyx Bio is a biotechnology firm founded in 2025 in New York, US, that specializes in gene therapy solutions. The company raised USD 4. 00 mn in SEED funding on October 1, 2025, led by 2048 Ventures with participation from New York Ventures, White Mug Healthcare, AIN Ventures, and Pathway Bioventures.

The firm has completed a total of 1 deal to date. Nionyx Bio specializes in gene therapy solutions designed to enhance precision and safety in the delivery of genetic materials, with a primary focus on treating kidney-related conditions. Their core offerings include innovative delivery systems characterized by purpose-built capsids and cassettes that facilitate targeted gene therapy. These products aim to solve critical challenges in the safe and effective delivery of therapeutic genes, thereby improving patient outcomes.

Nionyx serves a diverse clientele, including healthcare providers and research institutions, particularly within the North American and European markets, who seek advanced solutions for genetic disorders and tissue-specific therapies. Nionyx Bio generates revenue through strategic partnerships and B2B transactions with healthcare organizations and research entities. The company’s revenue model is centered around long-term collaborations, where clients invest in Nionyx’s proprietary technologies for gene delivery solutions. Specific transactions may involve licensing agreements or contracts for the exclusive use of their flagship products in clinical trials and therapeutic applications.

While detailed pricing plans for individual services or products are not disclosed, the company's positioning in the market suggests a focus on high-value agreements with stakeholders in the biotechnology and pharmaceutical sectors. Nionyx Bio plans to utilize the USD 4. 00 mn raised in seed funding to support the development of new products aimed at addressing kidney-related conditions. The company is also targeting expansion into the European market by the end of 2026.

The recent funding will assist in enhancing their research and development capabilities to bring innovative gene therapy solutions to market.